Abstract Library

#4318 Management of asymptomatic, sporadic, small non-functional pancreatic neuroendocrine tumours: Active surveillance or surgery? A retrospective cohort study in the SEER database

Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) exhibit a wide heterogeneity of aggressiveness and optimal management of asymptomatic, sporadic, small PanNETs remains controversial.

Conference:

Presenting Author: Chen C

Authors: Chen C, Zheng Z, Li P, Hu H,

Keywords: Pancreatic neuroendocrine tumour, surveillance, surgery, prognosis, SEER,

#4243 Role of gastric mucosa evaluation in diagnostic of pancreatic neuroendocrine tumors functional status

Introduction: Accessibility of high-precision imaging dramatically increased detection rate of small asymptomatic pancreatic neuroendocrine tumors (PanNETs). Functioning status is indication for surgical treatment with high perioperative risks, while increased level of NET markers could be associated with gastric mucosa atrophy or intake of proton pump inhibitors (PPI) and nor with tumor secretion.

Conference:

Presenting Author:

Authors: Salimgereeva D, Feidorov I, Konyakhina A,

Keywords: PanNET, chronic atrophic gastritis, marker, OLGA, anti-parietal cell antibodies,

#3818 Somatostatin analogues or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors

Introduction: Non-functioning (NF), sporadic, G1-G2 pancreatic neuroendocrine tumors (PanNETs) usually display an indolent course. Surgery is the first-choice treatment for localized tumors >2 cm. Unresectable or metastatic PanNETs expressing somatostatin receptors (SSTRs) are treated with somatostatin analogues (SSAs). The PROMID and the CLARINET studies proved the SSA antiproliferative effect in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The standard treatment for patients with PanNETs ≤2cm is active surveillance (AS). Yet no evidence of the value of SSA treatment exist in such patient population.

Conference:

Presenting Author: Maratta M

Authors: Maratta M, Chiloiro S, Raia S, Maiorano B, Rossi E,

Keywords: PanNET, somatostatin analogues, efficacy, surveillance, medical treatment,

#3482 PANDORA-2 protocol - Intervention study to improve quality of life in patients with small (≤2 cm) non-functional pancreatic neuroendocrine tumors

Introduction: Current guidelines changed the treatment strategy for small (≤2cm) non-functioning pancreatic neuroendocrine tumors (NF-pNET) from tumor resection to an active surveillance strategy. The previous PANDORA-1 (2021) study showed excellent clinical outcomes after a median follow-up of 17 months, where 89% of patients had pNETs without any tumor growth and only 3% of patients had tumor growth leading to a resection. Despite these results, the quality of life (QoL) was decreased at baseline and during follow-up. Furthermore, there was suboptimal adherence to the advised surveillance protocol.

Conference:

Presenting Author: Chen J

Authors: Chen J, Heidsma C, Engelsman A, Nieveen van Dijkum E,

Keywords: neuroendocrine, pancreatic, quality of life, ≤2 cm, non-functional, protocol,

#3249 Active surveillance as a treatment option for pancreatic neuroendocrine tumors in the context of MEN1

Introduction: Pancreatic neuroendocrine tumors include the second most common clinical manifestation of MEN1. Active surveillance has been proposed as a treatment option for patients with small gastrinomas as well as for MEN1 patients with small non-functioning pNETs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Yiannakopoulou E,

Keywords: active surveillance, gastrinoma, non-functioning pNETs, MEN1,